Pharmacotherapy of corneal transplantation

Bibliography

• Kalayoglu M. Emerging techniques in corneal transplantation: focus on Deep Lamellar Endothelial Keratoplasty (DLEK). Available from: http://www.ophthalmologyweb.com/Tech-Spotlights/26433-Emerging-Techniques-in-Corneal-Transplantation-Focus-on-Deep-Lamellar-Endothelial-Keratoplasty-DLEK/ 2005
   Google Scholar
• Rycroft B. Corneal Grafts. 1st edition. Butterworth & Co. Ltd.; London: 1955
   Google Scholar
• Wikipedia. Eduard Zirm. Available from: http://en.wikipedia.org/wiki/Eduard_Zirm 2012. [Accessed 15 December 2011]
   Google Scholar
• Moffatt SL, Cartwright VA, Stumpf TH. Centennial review of corneal transplantation. Clin Experiment Ophthalmol 2005;33:642-57
   PubMed Web of Science ®Google Scholar
• Melles GR, Eggink FA, Lander F, A surgical technique for posterior lamellar keratoplasty. Cornea 1998;17:618-26
   PubMed Web of Science ®Google Scholar
• Melles GR, Ong TS, Ververs B, Descemet membrane endothelial keratoplasty (DMEK). Cornea 2006;25:987-90
   PubMed Web of Science ®Google Scholar
• Anshu A, Price MO, Price FW Jr. Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. Ophthalmology 2012;119(3):536-40
   PubMed Web of Science ®Google Scholar
• Boruchoff S. Penetrating keratoplasty. In: Albert D, Jakobiec F, editors. Principles and Practice of Ophthalmology. W.B. Saunders; Philedelphia: 1994. p. 325-37
   Google Scholar
• Price MO, Thompson RW Jr, Price FW Jr. Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol 2003;121:1087-92
   PubMed Web of Science ®Google Scholar
• Thompson RW Jr, Price MO, Bowers PJ, Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003;110:1396-402
   PubMed Web of Science ®Google Scholar
• Williams KA, Muehlberg SM, Lewis RF, Long-term outcome in corneal allotransplantation. The Australian Corneal Graft Registry. Transplant Proc 1997;29:983
   PubMedGoogle Scholar
• Ing JJ, Ing HH, Nelson LR, Ten-year postoperative results of penetrating keratoplasty. Ophthalmology 1998;105:1855-65
   PubMed Web of Science ®Google Scholar
• Van Rensburg PD, Raber IM, Laibson PR, Management of primary corneal graft failure. Cornea 1998;17:208-11
   PubMed Web of Science ®Google Scholar
• Claerhout I, Beele H, Kestelyn P. Graft failure: I. Endothelial cell loss. Int Ophthalmol 2008;28:165-73
   PubMedGoogle Scholar
• Williams KA, Muehlberg SM, Lewis RF, How successful is corneal transplantation? A report from the Australian Corneal Graft Register. Eye (Lond) 1995;9(Pt 2):219-27
   PubMed Web of Science ®Google Scholar
• Jonas JB, Rank RM, Budde WM. Immunologic graft reactions after allogenic penetrating keratoplasty. Am J Ophthalmol 2002;133:437-43
   PubMed Web of Science ®Google Scholar
• Bourne WM, Hodge DO, Nelson LR. Corneal endothelium five years after transplantation. Am J Ophthalmol 1994;118:185-96
   PubMed Web of Science ®Google Scholar
• Patel SV, Hodge DO, Bourne WM. Corneal endothelium and postoperative outcomes 15 years after penetrating keratoplasty. Trans Am Ophthalmol Soc 2004;102:57-65
   PubMedGoogle Scholar
• Bourne WM. Cellular changes in transplanted human corneas. Cornea 2001;20:560-9
   PubMed Web of Science ®Google Scholar
• Bell KD, Campbell RJ, Bourne WM. Pathology of late endothelial failure: late endothelial failure of penetrating keratoplasty: study with light and electron microscopy. Cornea 2000;19:40-6
   PubMed Web of Science ®Google Scholar
• Armitage WJ, Dick AD, Bourne WM. Predicting endothelial cell loss and long-term corneal graft survival. Invest Ophthalmol Vis Sci 2003;44:3326-31
   PubMedGoogle Scholar
• Reinhard T, Bohringer D, Sundmacher R. Accelerated chronic endothelial cell loss after penetrating keratoplasty in glaucoma eyes. J Glaucoma 2001;10:446-51
   PubMed Web of Science ®Google Scholar
• Bohringer D, Bohringer S, Poxleitner K, Long-term graft survival in penetrating keratoplasty: the biexponential model of chronic endothelial cell loss revisited. Cornea 2010;29:1113-17
   PubMed Web of Science ®Google Scholar
• Al-Swailem SA. Graft failure: II. Ocular surface complications. Int Ophthalmol 2008;28:175-89
   PubMedGoogle Scholar
• Chou L, Cohen EJ, Laibson PR, Factors associated with epithelial defects after penetrating keratoplasty. Ophthalmic Surg 1994;25:700-3
   PubMedGoogle Scholar
• Meyer RF, Bobb KC. Corneal epithelium in penetrating keratoplasty. Am J Ophthalmol 1980;90:142-7
   PubMed Web of Science ®Google Scholar
• Thoft RA, Friend J. Corneal epithelial changes during midterm storage. Invest Ophthalmol 1976;15:82-8
   PubMedGoogle Scholar
• Machado RA, Mannis MJ, Mandel HA, The relationship between first postoperative day epithelial status and eventual health of the ocular surface in penetrating keratoplasty. Cornea 2002;21:574-7
   PubMed Web of Science ®Google Scholar
• Chang JH, Gabison EE, Kato T, Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-9
   PubMed Web of Science ®Google Scholar
• Feiz V, Mannis MJ, Kandavel G, Surface keratopathy after penetrating keratoplasty. Trans Am Ophthalmol Soc 2001;99:159-68
   PubMedGoogle Scholar
• Ayyala RS. Penetrating keratoplasty and glaucoma. Surv Ophthalmol 2000;45:91-105
   PubMed Web of Science ®Google Scholar
• Greenlee EC, Kwon YH. Graft failure: III. Glaucoma escalation after penetrating keratoplasty. Int Ophthalmol 2008;28:191-207
   PubMedGoogle Scholar
• Billingham RE, Krohn PL, Medawar PB. Effect of cortisone on survival of skin homografts in rabbits. Br Med J 1951;1(4716):1157-63
   PubMedGoogle Scholar
• Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res 2007;32(12):1005-16
   PubMed Web of Science ®Google Scholar
• Coster DJ, Williams KA. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation. Am J Ophthalmol 2005;140(6):1112-22
   PubMed Web of Science ®Google Scholar
• Yamagami S, Ebihara N, Usui T, Bone marrow-derived cells in normal human corneal stroma. Arch Ophthalmol 2006;124(1):62-9
   PubMedGoogle Scholar
• Hegde S, Beauregard C, Mayhew E, CD4(+) T-cell-mediated mechanisms of corneal allograft rejection: role of Fas-induced apoptosis. Transplantation 2005;79(1):23-31
   PubMed Web of Science ®Google Scholar
• Gillette TE, Chandler JW, Greiner JV. Langerhans cells of the ocular surface. Ophthalmology 1982;89(6):700-11
   PubMed Web of Science ®Google Scholar
• Niederkorn JY, Larkin DF. Immune privilege of corneal allografts. Ocul Immunol Inflamm 2010;18(3):162-71
   PubMed Web of Science ®Google Scholar
• Hamrah P, Zhang Q, Liu Y, Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. Invest Ophthalmol Vis Sci 2002;43(3):639-46
   PubMed Web of Science ®Google Scholar
• Pepose JS, Nestor MS, Gardner KM, Composition of cellular infiltrates in rejected human corneal allografts. Graefes Arch Clin Exp Ophthalmol 1985;222(3):128-33
   PubMed Web of Science ®Google Scholar
• Niederkorn JY, Stevens C, Mellon J, CD4+ T-cell-independent rejection of corneal allografts. Transplantation 2006;81(8):1171-8
   PubMed Web of Science ®Google Scholar
• Roelen DL, van Beelen E, van Bree SP, The presence of activated donor HLA class I-reactive T lymphocytes is associated with rejection of corneal grafts. Transplantation 1995;59(7):1039-42
   PubMed Web of Science ®Google Scholar
• Yamada J, Ksander BR, Streilein JW. Cytotoxic T cells play no essential role in acute rejection of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci 2001;42(2):386-92
   PubMed Web of Science ®Google Scholar
• Salisbury JD, Gebhardt BM. Blood group antigens on human corneal cells demonstrated by immunoperoxidase staining. Am J Ophthalmol 1981;91(1):46-50
   PubMed Web of Science ®Google Scholar
• Allansmith MR, Drell D, Kajiyama G, The role of tissue typing in corneal transplantation. Mod Probl Ophthalmol 1976;16:167-74
   PubMedGoogle Scholar
• Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea 2006;25:286-90
   PubMed Web of Science ®Google Scholar
• Rocha G, Deschenes J, Rowsey JJ. The immunology of corneal graft rejection. Crit Rev Immunol 1998;18:305-25
   PubMed Web of Science ®Google Scholar
• Meyer PA, Watson PG, Franks W, ‘Pulsed' immunosuppressive therapy in the treatment of immunologically induced corneal and scleral disease. Eye (Lond) 1987;1(Pt 4):487-95
   PubMed Web of Science ®Google Scholar
• BenEzra D, Griffin BW, Maftzir G, Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 1997;38:1954-62
   PubMed Web of Science ®Google Scholar
• Paliogianni F, Kincaid RL, Boumpas DT. Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways. J Exp Med 1993;178:1813-17
   PubMed Web of Science ®Google Scholar
• Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Front Biosci 2004;9:411-20
   PubMed Web of Science ®Google Scholar
• Banerjee S, Dick AD. Recent developments in the pharmacological treatment and prevention of corneal graft rejection. Expert Opin Investig Drugs 2003;12:29-37
   PubMed Web of Science ®Google Scholar
• Abrahams C, Gaillard V. Instillation of steroids in the eye: its effect on lymphocytes in regional lymph nodes and in peripheral blood. S Afr Med J 1980;57:993-5
   PubMed Web of Science ®Google Scholar
• The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. Arch Ophthalmol 1992;110:1392-403
   PubMedGoogle Scholar
• Hill JC. High risk corneal grafting. Br J Ophthalmol 2002;86:945
   PubMed Web of Science ®Google Scholar
• Borel JF, Feurer C, Gubler HU, Biological effects of cyclosporin A: a new antilymphocytic agent. 1976. Agents Actions 1994;43:179-86
   PubMedGoogle Scholar
• Banerjee S, Dick AD. Recent developments in the pharmacological treatment and prevention of corneal graft rejection. Expert Opin Investig Drugs 2003;12:29-37
   PubMed Web of Science ®Google Scholar
• Perry HD, Donnenfeld ED. Topical 0.05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 2004;5:2099-107
   PubMed Web of Science ®Google Scholar
• Acheampong AA, Shackleton M, Tang-Liu DD, Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res 1999;18:91-103
   PubMed Web of Science ®Google Scholar
• Bellot JL, Alio JL, Ruiz Moreno JM, Corneal concentration and systemic absorption of cyclosporin-A following its topical application in the rabbit eye. Ophthalmic Res 1992;24:351-6
   PubMed Web of Science ®Google Scholar
• Theng J, Zhou L, Tan D, Distribution of cyclosporin A in the cornea after topical or oral administration. J Ocul Pharmacol Ther 2002;18:83-8
   PubMed Web of Science ®Google Scholar
• Theng J, Zhou L, Tan D, Distribution of cyclosporin A in the cornea after topical or oral administration. J Ocul Pharmacol Ther 2002;18:83-8
   PubMed Web of Science ®Google Scholar
• Perry HD, Donnenfeld ED, Acheampong A, Topical cyclosporine A in the management of postkeratoplasty glaucoma and corticosteroid-induced ocular hypertension (CIOH) and the penetration of topical 0.5% cyclosporine A into the cornea and anterior chamber. CLAO J 1998;24:159-65
   PubMedGoogle Scholar
• Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 2010;18:352-61
   PubMed Web of Science ®Google Scholar
• Xi XH, Qin B, Jiang DY. Cyclosporin A combined with dexamethasone in preventing and treating immune rejection after penetrating keratoplasty. Hunan Yi Ke Da Xue Xue Bao 2003;28:627-30
   PubMedGoogle Scholar
• Inoue K, Kimura C, Amano S, Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty. Jpn J Ophthalmol 2001;45:378-82
   PubMed Web of Science ®Google Scholar
• Unal M, Yucel I. Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts. Br J Ophthalmol 2008;92:1411-14
   PubMed Web of Science ®Google Scholar
• Price MO, Price FW Jr. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology 2006;113:1785-90
   PubMed Web of Science ®Google Scholar
• Shimazaki J, Den S, Omoto M, Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation. Am J Ophthalmol 2011;152:33-9
   PubMed Web of Science ®Google Scholar
• Smolin G, Goodman D. Corneal graft reaction. Int Ophthalmol Clin 1988;28:30-6
   PubMedGoogle Scholar
• Coster DJ, Williams KA. Immunosuppression for corneal transplantation and treatment of graft rejection. Transplant Proc 1989;21:3125-6
   PubMedGoogle Scholar
• Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol 1991;35:369-85
   PubMed Web of Science ®Google Scholar
• Barker NH, Henderson TR, Ross CA, Current Australian practice in the prevention and management of corneal allograft rejection. Clin Experiment Ophthalmol 2000;28:357-60
   PubMed Web of Science ®Google Scholar
• Williams KA, Esterman AJ, Bartlett C, How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation 2006;81:896-901
   PubMed Web of Science ®Google Scholar
• Bohunicka E, Koza I, Kuzela S, Immunosuppression with cyclophosphamide: effect on antibody plaque-forming spleen cells and on hemolytic antibodies production. Neoplasma 1972;19:611-20
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De PR, Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8
   PubMed Web of Science ®Google Scholar
• Tabor DR, Kiel DP, Jacobs RF. Cyclophosphamide-sensitive activity of suppressor T cells during treponemal infection. Immunology 1987;62:127-32
   PubMed Web of Science ®Google Scholar
• Schoenwald RD, Houseman JA. Disposition of cyclophosphamide in the rabbit and human cornea. Biopharm Drug Dispos 1982;3:231-41
   PubMed Web of Science ®Google Scholar
• Kino T, Hatanaka H, Hashimoto M, FK-506, a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40:1249-55
   PubMed Web of Science ®Google Scholar
• Kino T, Hatanaka H, Miyata S, FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987;40:1256-65
   PubMed Web of Science ®Google Scholar
• Sawada S, Suzuki G, Kawase Y, Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987;139:1797-803
   PubMed Web of Science ®Google Scholar
• Busuttil RW, Holt CD. Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. Transplant Proc 1997;29:534-8
   PubMed Web of Science ®Google Scholar
• Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 1999;318:1104-7
   PubMed Web of Science ®Google Scholar
• Kobayashi C, Kanai A, Nakajima A, Suppression of corneal graft rejection in rabbits by a new immunosuppressive agent, FK-506. Transplant Proc 1989;21:3156-8
   PubMed Web of Science ®Google Scholar
• Hikita N, Lopez JS, Chan CC, Use of topical FK506 in a corneal graft rejection model in Lewis rats. Invest Ophthalmol Vis Sci 1997;38:901-9
   PubMed Web of Science ®Google Scholar
• Dickey JB, Cassidy EM, Bouchard CS. Periocular FK-506 delays allograft rejection in rat penetrating keratoplasty. Cornea 1993;12:204-7
   PubMed Web of Science ®Google Scholar
• Nishi M, Herbort CP, Matsubara M, Effects of the immunosuppressant FK506 on a penetrating keratoplasty rejection model in the rat. Invest Ophthalmol Vis Sci 1993;34:2477-86
   PubMed Web of Science ®Google Scholar
• Reis A, Reinhard T, Sundmacher R, Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. Transplant Proc 1998;30:4344-7
   PubMedGoogle Scholar
• Dhaliwal JS, Mason BF, Kaufman SC. Long-term use of topical tacrolimus (FK506) in high-risk penetrating keratoplasty. Cornea 2008;27:488-93
   PubMed Web of Science ®Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 2001;108:1838-44
   PubMed Web of Science ®Google Scholar
• Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005;153:701-5
   PubMed Web of Science ®Google Scholar
• Fermentek Biotechnology. Rapamycin (Sirolimus). Available from: http://www.fermentek.co.il/rapamycin.htm. 2012 [Accessed on 2 January 2012]
   Google Scholar
• Chatel MA, Larkin DF. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. Am J Ophthalmol 2010;150:179-84
   PubMed Web of Science ®Google Scholar
• Birnbaum F, Reis A, Bohringer D, An open prospective pilot study on the use of rapamycin after penetrating high-risk keratoplasty. Transplantation 2006;81:767-72
   PubMed Web of Science ®Google Scholar
• Reis A, Reinhard T, Voiculescu A, Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. Br J Ophthalmol 1999;83:1268-71
   PubMed Web of Science ®Google Scholar
• U.S.Food and Drug Administration. CellCept (mycophenolate mofetil) August 2009. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm177397.htm 2009. [Accessed 12 January 2012]
   Google Scholar
• Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. Int Ophthalmol 2008;28:223-32
   PubMedGoogle Scholar
• Sobrin L, Huang JJ, Christen W, Daclizumab for treatment of birdshot chorioretinopathy. Arch Ophthalmol 2008;126:186-91
   PubMed Web of Science ®Google Scholar
• Lupo L, Panzera P, Tandoi F, Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation 2008;86:925-31
   PubMed Web of Science ®Google Scholar
• Ramirez CB, Bozdin A, Frank A, Optimizing use of basiliximab in liver transplantation. Transpl Res Risk Manag 2010;2:1-10
   Google Scholar
• Birnbaum F, Jehle T, Schwartzkopff J, Basiliximab following penetrating risk-keratoplasty–a prospective randomized pilot study. Klin Monatsbl Augenheilkd 2008;225:62-5
   PubMed Web of Science ®Google Scholar
• O'Doherty M, Murphy CC. Update on immunosuppressive therapy for corneal transplantation. Int Ophthalmol Clin 2010;50:113-22
   PubMedGoogle Scholar
• Thiel MA, Coster DJ, Standfield SD, Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 2002;128:67-74
   PubMed Web of Science ®Google Scholar
• Pleyer U, Yang J, Knapp S, Effects of a selective glucocorticoid receptor agonist on experimental keratoplasty. Graefes Arch Clin Exp Ophthalmol 2005;243:450-5
   PubMed Web of Science ®Google Scholar
• Collins L, Fabre JW. A synthetic peptide vector system for optimal gene delivery to corneal endothelium. J Gene Med 2004;6:185-94
   PubMed Web of Science ®Google Scholar
• Adherence: Key Information on Managing and Treating Disease. 2012. 28-2-2012
   Google Scholar
• Winnick S, Lucas DO, Hartman AL, How do you improve compliance? Pediatrics 2005;115:e718-24
   PubMed Web of Science ®Google Scholar
• Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 2001;215:143-55
   PubMed Web of Science ®Google Scholar
• Fei WL, Chen JQ, Yuan J, Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty. J Ocul Pharmacol Ther 2008;24:235-44
   PubMed Web of Science ®Google Scholar